Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Possible Merger

13 Sep 2018 18:16

RNS Number : 7504A
Maven Income & Growth VCT 4 PLC
13 September 2018
 

Maven Income and Growth VCT 4 PLC

Maven Income and Growth VCT 2 PLC

 

13 September 2018

 

Possible merger of Maven Income and Growth VCT 4 PLC ("Maven VCT 4") and Maven Income and Growth VCT 2 PLC ("Maven VCT 2") (together the "Companies")

The boards of directors of the Companies announce that they have entered into discussions regarding a possible merger of the Companies (the "Merger"). These discussions may or may not lead to an agreement to merge the Companies. If the Merger is to proceed, the current intention is that it will be undertaken by way of a scheme of reconstruction under s.110 of the Insolvency Act 1986 by transferring the assets and liabilities of Maven VCT 2 to Maven VCT 4 in consideration for the issue of new ordinary shares in Maven VCT 4 to the Maven VCT 2 shareholders on a relative net asset value basis. A merger solely on this basis would be outside the provisions of The City Code on Takeovers and Mergers.

If the Merger is to proceed, it will require formal approval from the shareholders of both Companies. If the Merger is approved, it is expected to achieve costs savings through the establishment of a larger combined fund.

If the Merger proceeds, it is anticipated that the Prospectus and Circulars required under the Listing Rules and companies legislation would be despatched to shareholders in October 2018, with shareholder general meetings taking place in early November 2018, and completion in mid-November 2018.

A further announcement will be made in due course.

The information contained within this announcement is deemed by the Companies to constitute inside information as stipulated under the Market Abuse Regulations (EU number. 596/2014). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

For additional information, please contact:

Maven Capital Partners UK LLP

Secretary to the Companies

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

13 September 2018

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGGUUGBUPRGMW
Date   Source Headline
9th Nov 20233:49 pmRNSResult of General Meeting
13th Oct 20234:56 pmRNSPublication of a Prospectus
13th Oct 202310:17 amRNSDirector/PDMR Shareholding
13th Oct 202310:15 amRNSIssue of Equity - Dividend Investment Scheme
6th Oct 20232:39 pmRNSStatement re Dividend Investment Scheme
8th Sep 20235:01 pmRNSTransaction in Own Shares-Corrective announcement
7th Sep 20233:35 pmRNSTransaction in Own Shares
30th Aug 20232:02 pmRNSHalf-year Report
17th Aug 20233:26 pmRNSStatement re NAV and Interim Dividend
12th Jul 20234:09 pmRNSHolding(s) in Company
10th Jul 20235:06 pmRNSHolding(s) in Company
2nd Jun 202310:05 amRNSDirector/PDMR Shareholding
2nd Jun 20239:43 amRNSIssue of Equity
24th May 20235:10 pmRNSTransaction in Own Shares
23rd May 202310:18 amRNSDirector/PDMR Shareholding
23rd May 202310:17 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20233:38 pmRNSNet Asset Value(s) - Dividend Investment Scheme
11th May 20233:01 pmRNSResult of AGM
11th May 20232:20 pmRNSNet Asset Value(s)
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
13th Apr 20237:00 amRNSAnnual Financial Report
5th Apr 202312:36 pmRNSDirector/PDMR Shareholding
5th Apr 202312:30 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
21st Mar 20234:08 pmRNSTransaction in Own Shares
3rd Mar 20239:56 amRNSIssue of Equity
21st Feb 20234:11 pmRNSUnaudited NAV and Proposed Final Dividend
21st Feb 20233:10 pmRNSUnaudited Net Asset Value, Proposed Final Dividend
16th Feb 20237:00 amRNSStatement re Offer for Subscription
8th Feb 202310:24 amRNSDirector/PDMR Shareholding
8th Feb 202310:17 amRNSDirector/PDMR Shareholding
8th Feb 20239:44 amRNSIssue of Equity
3rd Feb 20233:12 pmRNSProvisional Net Asset Value
23rd Nov 20224:53 pmRNSTransaction in Own Shares
10th Nov 20223:33 pmRNSNet Asset Value(s)
9th Nov 20223:02 pmRNSResult of General Meeting
7th Oct 20224:28 pmRNSPublication of a Prospectus
7th Oct 20229:58 amRNSDirector/PDMR Shareholding
7th Oct 20229:51 amRNSIssue of Equity
4th Oct 20223:30 pmRNSChange of Auditor
3rd Oct 20223:08 pmRNSStatement re Dividend Investment Scheme
6th Sep 20224:48 pmRNSTransaction in Own Shares
2nd Sep 20223:30 pmRNSHalf-year Report
19th Aug 202210:47 amRNSStatement re NAV and Interim Dividend
14th Jul 20229:33 amRNSDirectorate Change
8th Jul 20223:28 pmRNSStatement re Joint Offers for Subscription
24th Jun 20224:13 pmRNSDirectorate Change
9th Jun 20224:18 pmRNSTransaction in Own Shares
6th Jun 20222:15 pmRNSIssue of Equity
20th May 202210:09 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.